Transfusion-Associated Graft-Versus-Host Disease in Adults.
Elmakki EE, Madkhali MA, Oraibi O, Alqassimi S, Saleh E.
Cureus. 2023 Aug 26;15(8):e44148. doi: 10.7759/cureus.44148. eCollection 2023 Aug.
Transfusion-associated graft-versus-host disease.
Rühl H, Bein G, Sachs UJ.
Transfus Med Rev. 2009 Jan;23(1):62-71. doi: 10.1016/j.tmrv.2008.09.006.
Transfusion-associated graft-versus-host disease.
Orlin JB, Ellis MH.
Curr Opin Hematol. 1997 Nov;4(6):442-8. doi: 10.1097/00062752-199704060-00015.
Transfusion-associated graft-versus-host disease (TA-GVHD) and graft-versus-host disease (GVHD): Pathophysiology and management (contrasted and compared).
Valsami S, Dryllis G, Papanastasi K, Kokoris S, Kriebardis A, Nikitiadis K, Konstantopoulos K, Politou M.
Hematol Oncol Stem Cell Ther. 2024 Oct-Dec 01;17(4):203-210. doi: 10.4103/hemoncstem.HEMONCSTEM-D-24-00043. Epub 2025 Jan 20.
Transfusion-associated graft-versus-host disease.
Dwyre DM, Holland PV.
Vox Sang. 2008 Aug;95(2):85-93. doi: 10.1111/j.1423-0410.2008.01073.x. Epub 2008 Jun 9.
Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA.
Transfus Apher Sci. 2022 Apr;61(2):103402. doi: 10.1016/j.transci.2022.103402. Epub 2022 Mar 11.
[Transfusion-associated graft-versus-host disease].
Bojanić I, Cepulić BG.
Lijec Vjesn. 2004 Jan-Feb;126(1-2):39-47.
Transfusion-associated graft-versus-host disease.
Rappeport JM.
Yale J Biol Med. 1990 Sep-Oct;63(5):445-54.
Transfusion-associated graft versus host disease in the immunocompetent patient: an ongoing problem.
Jawa RS, Young DH, Stothert JC, Kulaylat MN, Landmark JD.
J Intensive Care Med. 2015 Mar;30(3):123-30. doi: 10.1177/0885066613492645. Epub 2013 Jun 20.
Transfusion-associated graft-versus-host disease.
Schroeder ML.
Br J Haematol. 2002 May;117(2):275-87. doi: 10.1046/j.1365-2141.2002.03450.x.
